Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
gevokizumab · 5 trials · 4 indications
The Australian/Canadian (AUSCAN) Osteoarthritis Hand Index is a self-report assessment of pain, stiffness, and function in patients with hand osteoarthritis.
| Arm | Type | Description |
|---|---|---|
| gevokizumab | EXPERIMENTAL | Solution for subcutaneous injection |
| Placebo | PLACEBO_COMPARATOR | - |
| low dose gevokizumab | EXPERIMENTAL | - |
| high dose gevokizumab | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| gevokizumab | DRUG | - |
| Placebo | DRUG | Solution for subcutaneous injection |
Inclusion Criteria: * Autoimmune Inner Ear Disease with active deterioration in at least one ear * Failure to respond to a trial of high-dose corticosteroid therapy * Contraceptive measures adequate to prevent pregnancy during the study Exclusion Criteria: * Evidence of retrocochlear pathology (v...
Gevokizumab is an investigational small molecule being studied for acne vulgaris, autoimmune inner ear disease, osteoarthritis, and pyoderma gangrenosum. It has been evaluated in Phase 2 clinical trials for these conditions, all of which are completed. The drug is not approved and remains in clinical development.
Gevokizumab is being developed by XOMA Royalty Corporation, which trades under the ticker XOMA. The company has conducted Phase 2 trials of the drug across multiple indications, including acne vulgaris and osteoarthritis.
Gevokizumab is in Phase 2 clinical development. All four of its trials, which studied the drug in acne vulgaris, osteoarthritis, pyoderma gangrenosum, and autoimmune inner ear disease, are completed. It is investigational and not yet approved.
Gevokizumab has completed four Phase 2 trials: NCT01498874 for acne vulgaris (127 participants), NCT01683396 for osteoarthritis (87 participants), NCT01882504 for pyoderma gangrenosum (8 participants), and NCT01950312 for autoimmune inner ear disease (10 participants). All trials were conducted in the United States.
Gevokizumab is not FDA approved. It is an investigational drug that has completed Phase 2 clinical trials for acne vulgaris, osteoarthritis, pyoderma gangrenosum, and autoimmune inner ear disease. Its development status remains in clinical testing.